NCT02716012 2025-03-10
OUTREACH
Mina Alpha Limited
Phase 1 Unknown
Clinical Trials
83 trialsNCT04560894 2024-02-01
HCC
Sinocelltech Ltd.
Phase 2/3 Unknown
NCT06073730 2023-10-10
Viale-a
The Second Affiliated Hospital of Kunming Medical University
Phase 3 Unknown
NCT04135690 2023-08-15
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
Phase 2 Unknown
NCT05313958 2023-07-27
SCCLG-M5
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2/3 Unknown
NCT05889949 2023-06-07
Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma
Sun Yat-sen University
Unknown
NCT04387695 2023-02-16
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
First Affiliated Hospital of Zhejiang University
Phase 3 Unknown
NCT04992143 2023-02-16
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT05596968 2022-10-27
The Gut Microbiome and Sorafenib Maintenance Therapy in FLT3-ITD Positive AML After Allo-HSCT
Nanfang Hospital, Southern Medical University
Unknown
NCT05596981 2022-10-27
The Gut Microbiome in FLT3-ITD+ AML Undergoing Allo-HSCT With Or Without Sorafenib Maintenance After Allo-HSCT
Nanfang Hospital, Southern Medical University
Unknown
NCT05391867 2022-05-26
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
Sir Salimullah Medical College Mitford Hospital
Phase NA Unknown
NCT02794337 2022-04-27
TACE-SBRT
Tata Memorial Hospital
Phase 2/3 Unknown
NCT05113290 2022-01-27
Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment
First Affiliated Hospital Xi'an Jiaotong University
Phase 4 Unknown
NCT04752527 2021-11-15
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
The First Affiliated Hospital of Soochow University
Phase 2 Unknown
NCT01263951 2021-10-26
Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone
Thomas Jefferson University
Phase 2 Unknown
NCT01444807 2021-09-17
Evaluate the Efficacy of Sorafenib in Renal Cell Carcinoma Patients After a Radical Resection of the Metastases
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase 2 Unknown
NCT04127396 2021-07-23
Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT
Beijing Ditan Hospital
Phase 4 Unknown
NCT04926532 2021-06-15
Toripalimab
Shanghai Zhongshan Hospital
Phase 1/2 Unknown
NCT03971201 2021-04-14
A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion
White Plains Hospital
Phase 2 Unknown
NCT04229355 2021-02-09
DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 3 Unknown
NCT03794440 2021-01-22
A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2/3 Unknown
NCT03645980 2020-10-22
DKN-01 Inhibition in Advanced Liver Cancer
Johannes Gutenberg University Mainz
Phase 1/2 Unknown
NCT04143191 2020-03-25
SOURCE
Sun Yat-sen University
Phase 3 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT02504983 2020-02-05
Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma
Chang Gung Memorial Hospital
Phase 4 Unknown
NCT02436902 2020-01-10
A-TACE/S-HCC
Guangxi Medical University
Phase 3 Unknown
NCT04163237 2019-11-14
Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer
Guangxi Medical University
Phase 3 Unknown
NCT04152356 2019-11-05
Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma
Guangxi Medical University
Unknown
NCT04069949 2019-10-25
STUHCCPVTT
Sichuan University
Phase 1/2 Unknown
NCT02733809 2019-08-20
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
King Saud University
Phase 4 Unknown
NCT02529761 2019-08-01
TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma
Air Force Military Medical University, China
Phase NA Unknown
NCT00499525 2019-05-03
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
Northwestern University
Phase 2 Unknown
NCT03812770 2019-04-17
Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC
Sun Yat-sen University
Phase 2 Unknown
NCT03812783 2019-01-23
HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC
Sun Yat-sen University
Phase 2 Unknown
NCT03775395 2019-01-03
HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC
Sun Yat-sen University
Phase 3 Unknown
NCT03730675 2018-12-21
Irradiation Stent Placement Plus TACE for HCC and PVTT
Zhongda Hospital
Phase NA Unknown
NCT03518502 2018-05-08
Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis
Korea University
Phase 4 Unknown
NCT02836847 2018-05-07
Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma
Shanghai Jiao Tong University School of Medicine
Phase 2 Unknown
NCT01135056 2018-04-24
SIRveNIB
Singapore General Hospital
Phase 3 Unknown
NCT03468231 2018-03-16
HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC
Sun Yat-sen University
Phase 3 Unknown
NCT03178656 2017-12-21
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
Huazhong University of Science and Technology
Phase 4 Unknown
NCT02311205 2017-12-18
COTSOM
Asan Medical Center
Phase 2 Unknown
NCT01217034 2017-10-31
TACTICS
Kindai University
Phase 2 Unknown
NCT02330783 2017-05-09
Efficacy and Safety of Bevacizumab Plus Sorafenib for the Third-line Treatment in Metastatic Renal Cancer Patients
Peking University Cancer Hospital & Institute
Phase 2 Unknown
NCT01470495 2017-03-28
REPEAT
Southwest Hospital, China
Phase NA Unknown
NCT02187081 2017-03-28
Radiofrequency Ablation Accompanied With Spontaneous Sorafenib in Early to Intermediate Stage HCC
Southwest Hospital, China
Phase NA Unknown
NCT02015728 2016-12-15
SEED
Seattle Children's Hospital
Phase NA Unknown
NCT02013089 2016-08-30
GITIC
Sun Yat-sen University
Phase NA Unknown
NCT02423239 2016-04-06
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
e-Therapeutics PLC
Phase 1 Unknown
NCT02537158 2016-03-15
Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection
ChineseAMS
Phase NA Unknown